In a 25-year-old woman with four months of fatigue, myalgia, arthralgia, recent weight loss, decreased appetite, a 3‑cm circular patch of scalp hair loss, and scaly erythematous facial plaques, which initial laboratory study is most appropriate to determine the diagnosis?

ANA Testing is the Most Appropriate Initial Laboratory Study

In this 25-year-old woman presenting with systemic symptoms (fatigue, myalgia, arthralgia, weight loss) combined with characteristic cutaneous findings (circular scalp alopecia and scaly erythematous facial plaques), ANA testing should be ordered first as it is the mandatory screening test for systemic lupus erythematosus (SLE), which is the most likely diagnosis.

Clinical Reasoning

The constellation of findings strongly suggests SLE:

• Systemic manifestations: Four months of constitutional symptoms (fatigue, myalgia, arthralgia, weight loss, decreased appetite)
• Cutaneous involvement: Scaly erythematous facial plaques (consistent with malar or discoid rash) and circular scalp alopecia (discoid lupus or alopecia areata)
• Demographics: Young woman in the typical age range for SLE onset

Why ANA Testing First

ANA positivity on HEp-2 cells is a mandatory entry criterion for SLE classification under current criteria 1. This makes it the logical first-line screening test when SLE is suspected. The test has high sensitivity (>95%) for SLE, making it an excellent rule-out test.

Important Caveat About ANA-Negative SLE

While ANA testing should be performed first, you must be aware that ANA-negative SLE exists and can present with severe manifestations 2. Recent systematic review data shows that cutaneous manifestations are the most common presentation in ANA-negative SLE, followed by photosensitivity and joint complaints 2—exactly matching this patient's presentation.

If the ANA is negative but clinical suspicion remains high, do not stop there. Research demonstrates that nearly 100% of ANA-negative SLE patients have anti-Ro/SSA antibodies when tested by sensitive ELISA methods 3. Additionally, 46% have anti-La/SSB and 35% have anti-U1RNP 3.

Why Not the Other Tests Initially

• Complement C3/C4: These are useful for assessing disease activity and monitoring in established SLE, particularly with renal involvement, but are not first-line diagnostic tests
• Serum cortisol: Would evaluate for Addison's disease, but the cutaneous findings (scaly erythematous plaques and circular alopecia) are not consistent with adrenal insufficiency
• TSH: While hypothyroidism can cause fatigue and weight changes, it does not explain the inflammatory skin findings, myalgia, or arthralgia
• Dehydroepiandrosterone (DHEA): Not a standard diagnostic test for this presentation

Algorithmic Approach

1. Order ANA testing first as the mandatory screening test
2. If ANA is positive: Proceed with reflex testing for specific antibodies (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-U1RNP) and complement levels
3. If ANA is negative but clinical suspicion remains high: Order specific antibody testing anyway, particularly anti-Ro/SSA by sensitive ELISA 3, 2, as this patient's presentation (cutaneous disease with systemic symptoms) is classic for ANA-negative SLE
4. Consider additional workup including CBC, comprehensive metabolic panel, urinalysis, and ESR/CRP

Common Pitfall to Avoid

Do not dismiss SLE based solely on a negative ANA. The most recent evidence emphasizes that ANA-negative SLE is a recognized entity, with cutaneous manifestations being the predominant feature 2. Anti-Ro/SSA antibodies are present in virtually all these cases when sensitive testing methods are used 3.